In line with this, mechanistic studies indicate that soy isoflavones may affect various pathologically active signaling pathways in prostate cancer cells, downregulate the cancer cell androgen receptors, decrease the expression of prostate-specific antigen and matrix metalloproteinase, reverse prostate cancer cell epithelial to mesenchymal transition, contribute to epigenetic changes associated with the fate of cancer cells and suppress the angiogenesis that follows prostate cancer growth (Ajdžanović et al., 2019[1]). Here, AR is linked to cancer.